Akuru Pharma Competitors and Similar CompaniesClear all
Akuru Pharma's competitors and similar companies include CytomX Therapeutics, Pharmacyclics, Ascendis Pharma and Arcus Biosciences.
 Akuru Pharma Akuru Pharma is a company exploiting transporter proteins for diagnosis and treatment of kidney cancer.
|  CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform. |  Pharmacyclics Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. |  Ascendis Pharma Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology. |  Arcus Biosciences Arcus Biosciences is a biotech company that visions to create new cancer therapeutics through the use of emerging insights in immunology. | |
Founding Date | Founding Date 2016 | Founding Date 2008 | Founding Date 1991 | Founding Date 2007 | Founding Date 2015 |
Type | Type Private | Type Public | Type Subsidiary | Type Public | Type Public |
Tags | |||||
Locations | Locations Lund, SE HQ | Locations South San Francisco, US HQ | Locations Sunnyvale, US HQ | Locations Hellerup, DK HQ Heidelberg, DE Palo Alto, US | Locations Hayward, US HQ |
Employees | Employees 1 | Employees 15815% increase | Employees 6711% decrease | Employees 879 | Employees 500502% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 78 m | Valuation ($) N/A | Valuation ($) 7.7 b | Valuation ($) 1.5 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $101.2m (FY, 2023) | Revenue (est.) $729.7m (FY, 2014) | Revenue (est.) €266.7m (FY, 2023) | Revenue (est.) $117m (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $40.4m (FY, 2014) | Cost of goods €41.9m (FY, 2023) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $689.3m (FY, 2014) | Gross profit €224.8m (FY, 2023) | Gross profit N/A |
Net income | Net income N/A | Net income ($569k) (FY, 2023) | Net income $86.1m (FY, 2014) | Net income (€481.4m) (FY, 2023) | Net income ($307m) (FY, 2023) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 132.4m | Total funding raised N/A | Total funding raised $ 85.8m | Total funding raised $ 70m |
For sources of this data, please see the company profile
View Company Profiles
CytomX Therapeutics
HQ
South San Francisco, US
Employees
158↑ 15% increase
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.
View companyPharmacyclics
HQ
Sunnyvale, US
Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
View companyAscendis Pharma
HQ
Hellerup, DK
Employees
879
Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology.
View companyArcus Biosciences
HQ
Hayward, US
Employees
500
Arcus Biosciences is a biotech company that visions to create new cancer therapeutics through the use of emerging insights in immunology.
View company